Charles Elliott Sigal insider trades

Open-market stock purchases and sales by Charles Elliott Sigal, Director at Vir Biotechnology, Inc, from SEC Form 4 filings since May 16, 2016.

Track record: 0% of 8 scored buys are up 5% or more since purchase, averaging -77%.

Recent trades

DateStockTradeValue
May 27, 2026VIR Vir Biotechnology, IncBought (not open market)—
May 27, 2026VIR Vir Biotechnology, IncBought (not open market)—
May 20, 2026ALNY Alnylam Pharmaceuticals, IncBought (not open market)—
May 20, 2026ALNY Alnylam Pharmaceuticals, IncBought (not open market)—

Companies traded

  • VIR Vir Biotechnology, Inc: 4 buys, last May 27, 2026
  • ALNY Alnylam Pharmaceuticals, Inc: other filings, last May 20, 2026
  • SURF Surface Oncology, Inc: other filings, last Sep 8, 2023
  • ADAP Adaptimmune Therapeutics plc: 4 buys, last Jul 3, 2023

Get free alerts when Charles Elliott Sigal files a new trade →